http://orcid.org/0000-0002-1068-4261
References
- Hosaka S, Murayama N, Satsukawa M, et al. (2015). Comprehensive evaluation for substrate selectivity of cynomolgus monkey cytochrome P450 2C9, a new efavirenz oxidase. Drug Metab Dispos 43:1119–22.
- Kelley RW, Reed JR, Backes WL. (2005). Effects of ionic strength on the functional interactions between CYP2B4 and CYP1A2. Biochemistry 44:2632–41.
- Mayumi K, Hanioka N, Masuda K, et al. (2013). Characterization of marmoset CYP2B6: cDNA cloning, protein expression and enzymatic functions. Biochem Pharmacol 85:1182–94.
- Murayama N, Minoshima M, Shimizu M, et al. (2007). Involvement of human cytochrome P450 2B6 in the omega- and 4-hydroxylation of the anesthetic agent propofol. Xenobiotica 37:717–24.
- Nishimura M, Yaguti H, Yoshitsugu H, et al. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. Yakugaku Zasshi 123:369–75.
- Sasaki E. (2015). Prospects for genetically modified non-human primate models, including the common marmoset. Neurosci Res 93:110–5.
- Shimada T, Yamazaki H, Mimura M, et al. (1994). Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414–23.
- Shimizu M, Iwano S, Uno Y, et al. (2014). Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. PLoS One 9:e100936.
- Uehara S, Uno Y, Inoue T, et al. (2015a). Novel marmoset cytochrome P450 2C19 in livers efficiently metabolizes human P450 2C9 and 2C19 substrates, S-warfarin, tolbutamide, flurbiprofen, and omeprazole. Drug Metab Dispos 43:1408–16.
- Uehara S, Uno Y, Inoue T, et al. (2015b). Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix jacchus). Drug Metab Dispos 43:735–42.
- Uehara S, Uno Y, Inoue T, et al. (2015c). Substrate selectivities and catalytic activities of marmoset liver cytochrome P450 2A6 differed from those of human P450 2A6. Drug Metab Dispos 43:969–76.
- Uehara S, Uno Y, Suzuki T, et al. (2016). Strong induction of cytochrome P450 1A/3A, but not P450 2B, in cultured hepatocytes from common marmosets and cynomolgus monkeys by typical human P450 inducing agents. Drug Metab Lett 10:244–53.
- Uehara S, Uno Y, Nakanishi K, et al. (2017). Marmoset cytochrome P450 3A4 orthologue expressed in liver and small intestine tissues efficiently metabolizes midazolam, alprazolam, nifedipine, and testosterone. Drug Metab Dispos 45:457–67.
- Uehara S, Uno Y, Oshio T, et al. (2018). Marmoset pulmonary cytochrome P450 2F1 oxidizes biphenyl and 7-ethoxycoumarin and hepatic human P450 substrates. Xenobiotica, in press. DOI:10.1080/00498254.2017.1354138
- Uno Y, Matsuno K, Nakamura C, et al. (2009). Identification and characterization of CYP2B6 cDNA in cynomolgus macaques (Macaca fascicularis). J Vet Med Sci 71:1653–6.
- Uno Y, Uehara S, Yamazaki H. (2016). Utility of non-human primates in drug development: comparison of non-human primate and human drug-metabolizing cytochrome P450 enzymes. Biochem Pharmacol 121:1–7.
- Utoh M, Miura T, Kusama T, et al. (2017). Efavirenz clearances in vitro and in vivo in six cynomolgus monkeys associated with polymorphic cytochrome P450 2C9 and simulated by individual physiologically based pharmacokinetic models. Biopharm Drug Dispos 38:439–42.
- Wang H, Tompkins LM. (2008). CYP2B6: new insights into a historically overlooked cytochrome P450 isozyme. Curr Drug Metab 9:598–610.
- Yamazaki H, Ueng Y-F, Shimada T, Guengerich FP. (1995). Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 34:8380–9.